Hence, it is highly likely that PCSK9 inhibitors may inhibit both atherogenesis and atherothrombosis in hypercholesterolemia conditions, by disrupting CD36, LOX-1, and SARA expression [73,74]. The gene discussed is PCSK9; the disease is familial hypercholesterolemia.